South Korea’s Fair Trade Commission (FTC) will investigate e-commerce giant Coupang Inc. for suspicion of forcing employees to post false reviews on private brand (PB) products to attract customers, industry.
Civic groups had filed reports with the antitrust regulator about the suspected act by Coupang and its subsidiary CPLB.
While cases reported to the FTC are usually dealt with by regional offices, Coupang’s case will be handled by its headquarters due to the potential social impact.
Civic groups claimed in a press conference that Coupang mobilized employees without any proper compensation to write false reviews since last July.
Coupang supposedly wanted to bring more exposure to its private brand products.
The FTC is also investigating Coupang for manipulating algorithms to prioritize Coupang’s PB products on the top of its rankings since June.


Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Trump Administration Appeals Judge’s Order Limiting ICE Tactics in Minneapolis
Tesla Launches New Model Y Variant in the US Starting at $41,990
U.S. Stock Futures Rise as Investors Eye Big Tech Earnings and AI Momentum
UK Employers Plan Moderate Pay Rises as Inflation Pressures Ease but Persist
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
DOJ Urges Judge to Block Lawmakers’ Bid for Special Master in Jeffrey Epstein Records Case
Former South Korean President Yoon Suk Yeol Faces Historic Court Ruling Over Failed Martial Law Attempt
S&P 500 Rises as AI Stocks and Small Caps Rally on Strong Earnings Outlook
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War
Federal Judge Rules Trump Administration Unlawfully Halted EV Charger Funding
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 



